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Diagnostic Yield of Cytologic Analysis of Pericardial Effusion
in Dogs
L.A. Cagle, S.E. Epstein, S.D. Owens, M.S. Mellema, K. Hopper, and A.G. Burton
Background: Pericardial effusion cytology is believed by many to be of limited value, yet few studies have evaluated its
diagnostic utility.
Objectives: To determine the diagnostic utility of cytologic analysis of pericardial effusion in dogs and to determine if
consideration of additional data could improve the diagnostic yield.
Animals: Two hundred and fifty-nine dogs with cytologic analysis of pericardial effusion performed between April 1990
and June 2012.
Methods: Electronic medical records from a university teaching hospital were retrospectively reviewed; signalment,
complete blood count, serum biochemistry, cytologic analysis of pericardial effusion, and echocardiographic data were
recorded. Cytology was classified as diagnostic (infectious or neoplastic) or nondiagnostic (hemorrhagic or other) and
groups were compared with multiple Student’s t-tests.
Results: Cytology was grouped as nondiagnostic (92.3%) or diagnostic (7.7%) and characterized as hemorrhagic
(90%), neoplastic (4.6%), infectious (3.1%), or other (2.3%). Overall cytologic analysis of pericardial effusion diagnostic
utility was 7.7% and increased to 20.3% if the effusion hematocrit (HCT) <10%; echocardiographic evidence of a mass
did not result in a significant increase in the diagnostic utility.
Conclusions and Clinical Importance: The diagnostic utility of cytologic analysis of canine pericardial effusion is vari-
able depending on the underlying etiology. In this group of dogs, the diagnostic yield of cytologic analysis was greater for
pericardial effusion samples in which the HCT was less than 10%.
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Pericardial effusion has an overall prevalence of0.43% in dogs examined at a university teaching
hospital and occurs in approximately 7% of dogs with
clinical signs of cardiac disease.1,2 Etiologies include
septic pericarditis, coagulopathies, left atrial rupture,
neoplasia, and idiopathic pericardial effusion. Idio-
pathic effusions and cardiac hemangiosarcoma are the
most common etiologies whereas heart base tumors,
mesothelioma, and lymphoma occur less frequently.3,4
Prognosis varies greatly based on the underlying diag-
nosis and is poor to guarded for hemangiosarcoma
(median survival time 1–4 months) and good to excel-
lent for idiopathic effusions (survival time up to
4 years).5–9
Cytologic analysis of pericardial effusion provides an
accurate and definitive diagnosis when infectious agents
or lymphoma are the causative etiologies.5,10,11 Con-
versely, neoplastic diagnoses other than lymphoma (he-
mangiosarcoma, chemodectoma, mesothelioma) are
rarely diagnosed based on cytology alone and addi-
tional diagnostic tests performed on fluid or blood
samples have a poor ability to distinguish these from
non-neoplastic etiologies.3,5,8,12–14 Pericardial effusion
values for lactate, hematocrit (HCT), and urea nitrogen
are significantly higher whereas effusion values for pH,
bicarbonate, and chloride are significantly lower in neo-
plastic versus non-neoplastic effusions; although the
degree of overlap between the groups resulted in limited
value to this testing.13 The difference between periph-
eral and pericardial glucose values was significantly
greater in dogs with neoplasia than those without neo-
plasia.13 pH is a poor diagnostic marker for differentiat-
ing neoplastic from non-neoplastic effusions.12–14
Diagnostic utility was defined, for the purpose of
this study, as the ability to obtain an etiologic diagno-
sis. Similar to veterinary medicine, the diagnostic util-
ity of cytologic analysis of pericardial effusion in
human medicine is variable; overall the diagnostic util-
ity is between 24 and 26%.15,16 Although, with malig-
nant neoplastic effusions, the sensitivity is between 67
and 92% and identifying neoplastic cells in pericardial
effusion is considered to be an accurate method to dis-
tinguish malignant from benign pericardial effu-
sions.17–21 Diagnostic yield of pericardial effusion
analysis is improved with a combination of cytology as
well as pericardial and epicardial biopsy via pericar-
dioscopy.22
The sensitivity and specificity of cytologic analysis
of pericardial effusion in dogs is unknown and the
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diagnostic utility is considered to be limited, causing
some clinicians not to routinely submit effusions for
cytologic analysis.3,5,8 Examination of pericardial fluid
cytology diagnosed neoplasia erroneously in 4/31
(13%) and failed to identify 74% of the neoplastic
cases evaluated in one population of dogs.3 It is
unknown if clinical data available at initial diagnosis
can aid in predicting the diagnostic utility of the peri-
cardial effusion analysis before submission. The objec-
tive of this study was to determine the diagnostic
utility of cytologic analysis of pericardial effusion in a
large population of dogs and to evaluate if data avail-




Electronic medical records from the William R. Pritchard
Veterinary Medical Teaching Hospital at the University of Cali-
fornia, Davis were searched for dogs that had cytologic analysis
of pericardial effusion performed from April 1990 to June 2012.
Only the first cytologic analysis from a dog was included in the
study. Exclusion criteria were incomplete cytologic analysis
report, incomplete medical record, or a fluid analysis that was
not pericardial effusion, but was billed as such. For analysis, effu-
sion cytology was categorized as either diagnostic (infectious or
neoplastic) or nondiagnostic (hemorrhagic or other).
Data Collection
Signalment was recorded along with pericardial effusion data
including gross and supernatant appearance, total protein, total
red blood cell (RBC) and nucleated cell counts, a differential
white blood cell count, and a cytologic diagnosis. Complete
blood count and serum biochemistry profiles run at the time of
effusion analysis, if available, were recorded. Hematologic param-
eters were analyzed from April 1990 to August 2001 using a com-
mercially available analyzera and from September 2001 to June
2012 a different commercially available analyzerb was used using
the species-specific setting.c Pericardial effusion HCT was calcu-
lated based on the measured effusion RBC count and the mean
cell volume (MCV) from the CBC via a standard formula HCT
(%) = [MCV (fl) 9 RBC count (M/lL)]/10. If a CBC was not
available from a dog, the mean MCV of 67.8 (standard error of
mean = 0.4) from the CBC of all dogs was used for the calcula-
tion. Echocardiographic results performed by a board certified
cardiologist, if available, were recorded. Results of echocardiog-
raphy were subdivided into 3 groups: definite, suspicious, or no
cardiac mass identified on echocardiogram. Histopathologic
results of pericardial or cardiac tissue from either necropsy or
biopsy were recorded. For statistical analysis, the histopathologic
results were grouped into neoplastic and non-neoplastic diagno-
ses.
Cytology Review
Archived slides of pericardial effusion samples, when available,
were reviewed by a board certified clinical pathologist blinded to
the results in the medical record. Slides were reviewed to deter-
mine the underlying diagnosis and to subjectively reaffirm that
the previous differential leukocyte count was accurate. If a
sample was not available for review, then the original cytologic
diagnosis from a board certified clinical pathologist was used.
Cytologic diagnosis of the effusion, for the purpose of data
analysis, was classified as hemorrhagic, infectious (bacterial or
fungal) neoplastic, or other (nonhemorrhagic, non-neoplastic,
and noninfectious). Neoplastic or infectious effusions may have
had a hemorrhagic component, but if neoplastic or infectious
cells were identified, they were not classified as a hemorrhagic
effusion. Diagnosis was based off of cytology results alone, yet
was subsequently compared with a histologic diagnosis, when
available.
Statistics
Descriptive statistics were performed with commercially avail-
able software.d Multiple t-tests comparing dog demographics,
pericardial effusion data, CBC, and serum biochemistry were per-
formed for diagnostic versus nondiagnostic effusions. Samples
were then subgrouped based on presence or absence of a mass on
echocardiogram and a diagnostic or a nondiagnostic effusion.
Multiple t-tests comparing 47 separate variables from patient
demographics, pericardial effusion data, CBC, and serum bio-
chemistry were performed. A Bonferonni correction was utilized
and a P value of <.001 was considered significant. Receiver oper-
ating characteristic (ROC) curve analysis was performed on mea-
sured effusion RBC count and calculated HCT of the pericardial
fluid and whether effusion was diagnostic or nondiagnostic on
cytology. Categorical data were compared using chi-square or
Fisher’s exact test where appropriate. A P value <.05 was consid-
ered significant.
Results
A total of 306 cytologic samples were identified, 33
were subsequent analyses from the same dog, leaving a
total of 273 patient records identified as having cyto-
logic analysis of pericardial effusion. A total of 14
samples were excluded from the study; 8 of these were
excluded because of incomplete cytologic data, 2 were
excluded because of an incomplete medical record, and
4 were excluded as no cytologic analysis of pericardial
effusion had actually been performed. Two hundred
fifty-nine pericardial effusion analyses remained and
were included in this study with 249 slides available
for re-review of cytology.
Breeds most commonly represented were mixed
breed dogs (21%) Golden Retrievers (17%), Labrador
Retrievers (15%), and German Shepherds (4%). Med-
ian age was 9 years (range 1–16 years). Patient weight
was recorded at the time of initial presentation in
57.5% of cases, with the median weight being 32 kg
(range 2–71 kg). Males represented 59% of the study
population with 99/106 (93%) of the females spayed
and 98/153 (64%) of the males neutered. Complete
blood counts from 124 cases (47.9%) and serum bio-
chemistries from 108 cases (41.7%) were available.
Packed cell volume of the pericardial effusion was
available in 19/259 (7.3%) of the cases included in this
study, whereas the effusion total RBC count was avail-
able in 254/259 (98%) of the cases in this study.
Of the 259 cases included, 233 were hemorrhagic
(90%), 12 were confirmed neoplasia (4.6%), 8 were
infectious (3.1%), and 6 were classified as other (2.3%)
based on cytologic analysis. Cytologic analysis of peri-
cardial effusion was considered diagnostic in 20/259
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(7.7%) cases. Neoplastic effusions included round cell
neoplasia (n = 7), carcinoma (n = 1), atypical epithe-
liod cells (n = 3), and hemic neoplasia (n = 1). Round
cell neoplasia was further subdivided into lymphoma
(n = 5), histiocytic (n = 1), and undetermined round
cell neoplasia (n = 1). Infectious effusions were noted
in 8 cases: bacterial (n = 7) and fungal (Candida albi-
cans, n = 1). Six cases were classified into an “other”
category: chylous effusion (n = 3), transudate (n = 1),
modified transudate (n = 1), and marked neutrophilic
inflammation with mixed mesothelial reactivity (n = 1).
When diagnostic versus nondiagnostic cytology was
compared, there were significant differences in the peri-
cardial effusion total nucleated cell counts, neutrophil
counts, large mononuclear cell counts, total RBC
counts, HCT of the effusion, and serum albumin
(Table 1).
An echocardiogram was performed in 254/259
(98.1%) cases. Of those cases, 112 (44.1%) did not
have a mass identified on echocardiogram, 33 (13.0%)
were suspicious for a mass, and 109 (42.9%) had a
definite mass noted on echocardiogram. Diagnostic
and nondiagnostic effusion groups were subdivided
based on echocardiographic results (no mass, suspi-
cious for a mass, definite mass). Significant results of
multiple t-tests comparing effusion and patient charac-
teristics with no cardiac mass noted on echocardio-
gram are reported in Table 2. When a mass was visible
only total nucleated cell count (P = .007) and large
mononuclear cell count (P < .0001) remained signifi-
cant. There were no differences between groups in the
subgroup of patients in which a mass was considered
suspicious, but not definitive on echocardiogram. No
association between echocardiographic diagnosis of a
mass and a diagnostic pericardial effusion analysis was
noted via Fishers exact test (P = .21). Cases (n = 5)
that did not receive an echocardiogram by a cardiolo-
gist had an ultrasound performed by other clinic per-
sonnel to confirm the presence of pericardial effusion,
the final diagnosis in these cases included anticoagu-
lant rodenticide, right auricular hemangiosarcoma,
infectious pericarditis (n = 2), and one unknown etiol-
ogy.
Receiver operating characteristic curve analysis was
performed using effusion RBC count (Fig 1) and cal-
culated HCT. The ideal cutoff for pericardial effusion
RBC count was 1.35 M/lL with a sensitivity (95% CI)
of 78.9% (54.4–94.0%) and specificity (95% CI) of
73.2% (67.0–78.7%). The ideal cutoff for calculated
HCT was determined to be 10.1% with a sensitivity







Hematocrit (%) of effusion 24.9  17.8 5.7  4.5 <.0001
Effusion total RBC (M/lL) 3.6 9 106  2.6 9 106 9.7 9 105  6.9 9 105 <.0001
Effusion total nucleated cell count (cell/lL) 1.3 9 104  1.9 9 104 1.4 9 105  1.3 9 105 <.0001
Effusion neutrophil count (cell/lL) 8.1 9 103  1.5 9 104 8.0 9 105  1.3 9 105 <.0001
Effusion large mononuclear cell count (cell/lL) 3.1 9 103  6.2 9 103 2.3 9 104  2.9 9 104 <.0001
Serum albumin (g/dL) 2.7  0.5 2.1  0.6 .0002
Table 2. Data comparing diagnostic and nondiagnostic effusion cytology in dogs with no mass seen on echocar-







Hematocrit (%) of effusion 23.4  15.9 6.1  4.9 .0009
Effusion total RBC (M/lL) 3.5 9 106  2.3 9 106 6.7 9 105  7.5 9 105 .0009
Effusion total nucleated cell count (cell/lL) 1.1 9 104  1.2 9 104 1.1 9 105  1.3 9 105 <.0001
Effusion neutrophil count (cell/lL) 6.0 9 103  7.9 9 103 8.4 9 104  1.1 9 105 <.0001
Effusion large mononuclear cell count (cell/lL) 3.6 9 103  7.9 9 103 2.7 9 104  3.9 9 104 <.0001
Fig 1. Receiver operating characteristic curve analysis of peri-
cardial effusion red blood cell count. Area under the
curve = 0.80, P < .0001.
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(95% CI) of 84.2% (60.4–96.6%) and a specificity
(95% CI) of 71.9% (65.7–77.6%). Area under the
curve (95% CI) was 0.80 (0.74–0.86) for both effusion
RBC count and calculated HCT as a discriminatory
test for diagnostic versus nondiagnostic effusions on
cytology.
An effusion HCT of 10% and presence or absence
of a mass on echocardiogram were evaluated to see if
they could increase the diagnostic utility of cytologic
analysis of pericardial effusion (Table 3). The odds
ratio (95% CI) was 10.8 (3.4–33.5) for a sample being
in the diagnostic effusion group as compared to the
nondiagnostic group when the HCT<10%.
Histopathologic assessment was available in 101/259
(39.0%) of the cases with pericardial effusion. Of the
cases with histopathology available, biopsies repre-
sented 59/101 (58.4%) of the cases, necropsies repre-
sented 38/101 (37.6%), and 4/101 (4.0%) cases with
histopathology had both a biopsy and a necropsy.
Histopathology cases were subdivided into neoplastic
(n = 24) and non-neoplastic etiologies (n = 77). Of the
non-neoplastic biopsies, pericardial effusion was classi-
fied as hemorrhagic (n = 67), infectious (n = 5), neo-
plastic (n = 2), modified transudate (n = 1), and
chylous (n = 2), resulting in a false positive rate of 2/
77 (2.6%) for neoplasia. Of the neoplastic biopsies, the
pericardial effusion was characterized as hemorrhagic
in 22/24 (91.7%), resulting in a sensitivity of cytology
with histologically confirmed neoplasia of 2/24 (8.3%).
Pericardial effusion analysis compared to histologically
confirmed neoplasia to non-neoplasia was performed
and no statistically significant differences were noted
between the 2 groups.
The original cytologic interpretation was compared
to the reviewed cytologic interpretation and when clas-
sified as nondiagnostic and diagnostic effusions, 244/
249 (98%) of the reviewed cytologic interpretations
matched the initial interpretation. All cases initially
classified as neoplastic, infectious, or other were con-
firmed on re-evaluation of the pericardial effusion
slides.
Discussion
The overall diagnostic utility of cytologic analysis of
pericardial effusion was 7.7% in all cases and increased
to 20.3% in cases with an effusion HCT<10%, yet an
echocardiogram did not significantly alter the diagnos-
tic utility. Although performed at a university teaching
hospital, these results are likely comparable to other
populations as our study population and etiologies of
pericardial effusion are similar to those previously
reported.10,12,13,23
When nondiagnostic and diagnostic effusions were
compared, multiple differences were found. Effusion
total nucleated cells and neutrophil counts were higher
in the diagnostic group as the infectious effusion cases
had a significantly higher population of neutrophils
associated with that disease. Numbers of large mono-
nuclear cells were increased in the effusions of the
diagnostic group as expected in the infectious and the
neoplastic effusion cases. Serum albumin concentration
was decreased in the diagnostic group likely because of
the chronicity of the primary disease and an inflamma-
tory response.24 Dogs with neoplasia have been
reported to have a higher HCT in the pericardial fluid,
which is in contrast to our study in which patients
with a diagnosis based on cytology had a lower RBC
count and HCT.13 The difference is explainable by the
method of diagnosis, which was by echocardiography,
whereas ours was based on cytology. Cases in the pre-
vious study diagnosed with a right atrial mass (21/28
[75%] of enrolled cases) were considered to have a
neoplastic diagnosis and hence the high effusion HCT
associated with a neoplastic etiology. In contrast, only
cases with a pericardial effusion analysis were analyzed
in this study and animals with a cardiac mass on echo-
cardiogram were unlikely to have had an effusion sub-
mitted and therefore did not contribute substantially
to the diagnostic group.
The effusion HCT value in our study was calculated
based on a measured RBC count of the effusion and
the MCV from the peripheral blood. HCT was calcu-
lated as a post hoc value after the finding of a differ-
ence of RBC count in diagnostic effusions was
obtained. This post hoc analysis was performed, as
one of our goals was to identify a value at presenta-
tion that could increase the diagnostic yield of cyto-
logic analysis of pericardial effusion. In practice,
measurement of effusion PCV would be more readily
available than effusion HCT. Limitations to this analy-
sis are that the PCV and HCT are not directly inter-
changeable with the PCV being approximately 2–3%
higher than HCT and only 48% of our patients had
an MCV available.25 As the mean MCV was used for
HCT in roughly half of our population if any severe
micro- or macrocytosis existed in those dogs, it would
diminish the accuracy of our results. Additionally, the
Table 3. Number of cases with diagnostic and nondi-
agnostic effusions based on cytology stratified by effu-
sion hematocrit (HCT) (<10% or ≥10%) and whether







All cases (n = 254) 7.7
HCT ≥10% 165 4 2.4
HCT <10% 63 16 20.3a
No echocardiographic
mass (n = 108)
8.9
HCT ≥10% 73 3 3.9
HCT <10% 25 7 21.8a
Suspicious/definite
echocardiographic
mass (n = 141)
6.4
HCT ≥10% 96 2 2.0
HCT <10% 36 7 16.3a
aIndicates a difference in diagnostic utility between effusion
HCT groups P < .005.
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MCV of the peripheral blood might not have matched
the MCV of the effusion if the effusion formation was
not acute because chronicity could affect the MCV. It
should be noted that the difference still existed for
both measured effusion RBC count and calculated
HCT in statistical analysis (P < .0001) so the results
are likely valid. Calculation of the effusion HCT was
necessary because no cases in this study had a
measured effusion HCT.
The ideal cutoff for effusion HCT based on ROC
curve analysis was 10.1%, with lower HCT values hav-
ing an increased sensitivity for cytologic diagnosis. A
significant AUCROC value of 0.80 indicates that this is
a good discriminatory test for whether cytologic analy-
sis will be diagnostic or nondiagnostic. Ideally, mea-
sured RBC count from an automated hematology
analyzer would be used in clinical practice, but as this
test is not always available, and because of the differ-
ences in PCV and HCT mentioned above, the authors
propose the submission of any fluid with a PCV <12
to 13% as it is likely to have an increased diagnostic
yield relative to more hemorrhagic samples.
Comparing the cytologic diagnosis of neoplasia to
the histopathologic diagnosis, when available, resulted
in a false positive rate of 2.6% (2/77) and no cases
with a histopathologic diagnosis of neoplasia had an
equivalent cytologic diagnosis in our study. Both cases
that were considered a false positive had a cytologic
diagnosis of neoplasia. The first case had cytology
highly suggestive of hemangiosarcoma whereas the sec-
ond case had a diagnosis of hemorrhagic effusion with
atypical epitheliod cells and was interpreted as a malig-
nant epitheliod neoplasia. As cases with a definitive
diagnosis of neoplasia on cytology were unlikely to
have histopathology submitted, because a diagnosis
was already known, the true false positive rate remains
unknown.
Cytologic analysis of pericardial effusion has been
evaluated throughout the veterinary literature, but the
sensitivity and specificity of cytologic analysis are
currently ill defined. Unfortunately, without histopa-
thology being available in all cases, specificity and sen-
sitivity in a large group of dogs could not be
addressed in this retrospective study. Cytologic analy-
sis of pericardial effusion does not appear to be highly
sensitive for achieving a diagnosis with primary car-
diac neoplasms in people. However, it appears to have
a moderate to high sensitivity for metastatic neoplasia
(61–100%) and specificity for metastatic neoplasia in
human patients (93.3–100%).18,20 This variable diag-
nostic yield in human patients is explained by the dif-
ferences in the underlying etiology of pericardial
neoplasia. Human patients more commonly have meta-
static carcinoma effusions, which can be diagnosed on
cytology. Cytology is considered the gold standard for
detection of malignant neoplastic effusions in human
medicine because of the high sensitivity of cytologic
analysis of pericardial effusion.26–28 Cardiac angiosar-
coma is the most common malignant cardiac neoplasm
in adult human patients. Unlike metastatic carcinomas,
diagnosis of angiosarcoma is based on open cardiac
biopsy or surgical resection of a right atrial mass with
no data showing an ability to diagnose this tumor
based on effusion cytology alone. The diagnostic capa-
bilities of cytology for cardiac angiosarcoma appear to
be similar to what is seen in dogs with hemangiosarco-
ma resulting in differing diagnostic yields.22,28–31
The prevalence of a cardiac mass noted on echocar-
diogram was comparable to previous reports in the lit-
erature with 30 and 49.5% of pericardial effusion cases
reported to have a cardiac mass compared to 42.9%
with a definite or 13% with a suspicious mass on echo-
cardiogram in this study.4,23 With the increasing avail-
ability of ultrasound in veterinary practice, the
presence or absence of a cardiac mass was a potential
variable that could alter the diagnostic value of peri-
cardial effusion analysis. This, however, failed to reach
statistical significance as a sole preanalytical variable.
When effusion HCT is combined with the absence of a
mass on echocardiography, the combination of the
two does not result in a significant change in the diag-
nostic utility. The maximal diagnostic yield of 21.8%
found in this study was in the subgroup of dogs with
no identifiable mass on echocardiography and an effu-
sion HCT <10% compared to the overall yield of
7.7%. This yield represents an increase in the cost–
benefit ratio to the client suggesting that if the effusion
and dog fit these criteria, submission of pericardial
effusion to a clinical pathologist gives a 3-fold
increased chance of receiving a specific diagnosis.
Limitations in this study include those inherent in
all retrospective studies; the data evaluated were
incomplete with regard to age, weight, complete blood
counts, and serum biochemistry data. Variability exists
within the cytologic diagnosis because of different
clinical pathologists interpreting the slides. Slides were
re-evaluated in a blinded fashion to reduce this vari-
ability, yet a small percentage of slides were not avail-
able for re-evaluation. Echocardiograms were
performed by a variety of individuals. Each scan was
performed by either a board-certified cardiologist or a
supervised cardiology resident, yet variation will be
present because of examiner skill level variability. Con-
firmation of a cytologic diagnosis was limited based on
histopathology as only 39% of the cases included in
this study had concurrent histopathology available pre-
cluding true sensitivity and specificity analysis. Cases
available for inclusion in this study are not representa-
tive of the entire population of pericardial effusion in
dogs because not all cases with pericardial effusion
had a sample submitted for cytology.
Predicting the diagnostic utility based on the preli-
minary data (effusion HCT/PCV) and a noninvasive
diagnostic modality (echocardiogram) helps the clini-
cian to decide if sample submission is appropriate. The
overall diagnostic utility improves from 7.7 to 20.3%
with an effusion HCT <10%, yet an echocardiogram
did not significantly improve this diagnostic utility,
suggesting that submitting fluid for cytologic analysis
if the PCV <12 to 13% will have an increased yield.
Despite previous reports concluding a poor diagnostic
utility, we conclude that the diagnostic value of
70 Cagle et al
pericardial effusion cytologic analysis is variable
depending on the etiology.
Footnotes
a Baker Systems 9110 Plus Hematology Analyzer; BioChem
ImmunoSystems Inc, Allentown, PA
b ADVIA 120 Hematology System; Siemens Healthcare Diagnos-
tics Inc, Tarrytown, NY
c MultiSpecies System Software; Siemens Medical Solutions
Diagnostics Inc, Tarrytown, NY
d GraphPad Prism 6.0; Graph Pad Software, La Jolla, CA
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